Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Drug: SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT05482568
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
Phase 2
Completed
- Conditions
- Autoimmune Hepatitis
- Interventions
- Drug: HR19042 Capsules
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT05476900
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05473468
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 153
- Registration Number
- NCT05473624
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.
Phase 2
- Conditions
- Pain
- Interventions
- Drug: SHR8554 Injection and SHR0410 InjectionDrug: SHR8554 Injection and Placebo for SHR0410 Injection
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05470049
A Study to Evaluate the Efficacy and Safety of HR18042 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.
Phase 2
- Conditions
- Pain
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05470075
- Locations
- 🇨🇳
West China Hospital of Stomatology Sichuan University, Chengdu, Sichuan, China
A Trial of SHR0410 Injection for the Treatment of Pain After Laparoscopic Surgery
Phase 3
- Conditions
- Postoperative Pain Of Laparoscopic Surgery
- Interventions
- Drug: SHR0410 InjectionDrug: Placebo
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT05459220
A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids
Phase 2
Recruiting
- Conditions
- Uterine Fibroids With Menorrhagia
- Interventions
- Drug: PlaceboSHR7280 tablets blank preparationDrug: SHR7280 tablets
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT05442827
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05440006
- Locations
- 🇨🇳
Wannan Medical College Yijishan Hospital, Wuhu, Anhui, China
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05425472
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath